Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma

Erika Resetkova, Ana M. Gonzalez-Angulo, Nour Sneige, Timothy J. Mcdonnell, Aman U. Buzdar, Shu Wan Kau, Yuko Yamamura, James M. Reuben, Gabriel N. Hortobagyi, Massimo Cristofanilli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


BACKGROUND. Inflammatory breast carcinoma (IBC) is a rare and aggressive malignancy. Therapy for patients with IBC is multidisciplinary, and response to preoperative chemotherapy is considered an important predictor of outcome. Although only a limited number of molecular markers have been investigated in this setting, none has exhibited prognostic value for patients with IBC. METHODS. Immunohistochemical assays for P53, MDM-2, and MUC-1 were performed retrospectively to evaluate potential correlations between these markers and pathologic response, time to progression (TTP), and overall survival (OS) in 19 patients with IBC. RESULTS. After a median follow-up period of 46 months, patients with tumors that overexpressed P53 and did not express MUC-1 had a significantly shorter median TTP and median OS compared with other patients. CONCLUSIONS. Expression of P53 and MUC-1 may be predictive of treatment efficacy and outcome for patients with IBC. Furthermore, these two markers may represent novel therapeutic targets in such patients.

Original languageEnglish (US)
Pages (from-to)913-917
Number of pages5
Issue number5
StatePublished - Sep 1 2004


  • Inflammatory breast carcinoma
  • MDM-2
  • MUC-1
  • P53
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma'. Together they form a unique fingerprint.

Cite this